{"id":18866,"date":"2026-09-25T08:50:55","date_gmt":"2026-09-25T11:50:55","guid":{"rendered":"https:\/\/www.biolabeco.com.br\/?post_type=imprensa&#038;p=18866"},"modified":"2026-09-30T16:32:29","modified_gmt":"2026-09-30T19:32:29","slug":"biolab-has-been-selected-by-the-medicines-patent-pool-mpp-to-commercialize-a-new-antiviral-for-influenza","status":"publish","type":"imprensa","link":"https:\/\/www.biolabeco.com.br\/en\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/","title":{"rendered":"Biolab &amp; Co. is chosen by the Medicines Patent Pool (MPP) to market a new antiviral for influenza"},"content":{"rendered":"<p><em>Brazilian group is among the pharmaceutical companies selected for the voluntary licensing agreement signed between MPP and Roche<\/em><\/p>\n\n\n\n<p>Biolab &amp; Co. was selected by the Medicines Patent Pool (MPP) to offer the Brazilian market the antiviral baloxavir marboxil, from Roche, a new technology indicated for the treatment of influenza.<\/p>\n\n\n\n<p>The announcement was made on September 24, at an event held alongside the United Nations General Assembly in New York, dedicated to preparing the global response to pandemics. The selection of Biolab &amp; Co., along with other pharmaceutical companies, underwent a rigorous technical and regulatory evaluation process led by MPP, focused on expanding access to treatment in the 129 countries covered by the agreement, for which Biolab &amp; Co. is authorized to produce and supply the drug.<\/p>\n\n\n\n<p>The MPP is an international, non-profit public health organization supported by the UN, established in 2010. The model gained relevance during the Covid-19 pandemic, when it enabled the rapid expansion of antiviral production. Today, the MPP is considered by international organizations to be one of the most effective tools for anticipating access to treatments before a health emergency arises.<\/p>\n\n\n\n<p>\u201cThis sublicense is aligned with our mission to develop and deliver therapeutic solutions that generate value for patients and physicians, and that reach those who truly need them,\u201d states Fabio Amorosino, President of the Biolab &amp; Co Group. \u201cPandemics do not have an exact timetable and cannot wait for prolonged negotiations. Now we are ready, with a solid production base, to do our part in Brazil and the region.\u201d<\/p>\n\n\n\n<p>Baloxavir marboxil is a single-dose oral antiviral recommended by the World Health Organization for the treatment of influenza, including prophylaxis after exposure to the virus. The intended use scope in the agreement covers any indication approved by the FDA (USA) or the EMA (Europe).<\/p>\n\n\n\n<p>Starting with the sub-licence, Biolab &amp; Co. will, through Biolab Farma, one of the six companies in the group, begin the process of developing and registering the product in Brazil.<\/p>","protected":false},"featured_media":18871,"template":"","categories":[1576],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.4 (Yoast SEO v24.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biolab &amp; Co. \u00e9 escolhida pelo Medicines Patent Pool (MPP) para comercializar novo antiviral contra influenza - Biolab &amp; Co<\/title>\n<meta name=\"description\" content=\"A Biolab &amp; Co. foi selecionada pela Medicines Patent Pool (MPP) para oferecer ao mercado brasileiro o antiviral baloxavir marboxil, da Roche, nova tecnologia indicada para o tratamento da influenza.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biolabeco.com.br\/en\/press\/biolab-has-been-selected-by-the-medicines-patent-pool-mpp-to-commercialize-a-new-antiviral-for-influenza\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biolab &amp; Co. \u00e9 escolhida pelo Medicines Patent Pool (MPP) para comercializar novo antiviral contra influenza\" \/>\n<meta property=\"og:description\" content=\"A Biolab &amp; Co. foi selecionada pela Medicines Patent Pool (MPP) para oferecer ao mercado brasileiro o antiviral baloxavir marboxil, da Roche, nova tecnologia indicada para o tratamento da influenza.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biolabeco.com.br\/en\/press\/biolab-has-been-selected-by-the-medicines-patent-pool-mpp-to-commercialize-a-new-antiviral-for-influenza\/\" \/>\n<meta property=\"og:site_name\" content=\"Biolab &amp; Co\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-30T19:32:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"669\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/\",\"url\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/\",\"name\":\"Biolab &amp; Co. \u00e9 escolhida pelo Medicines Patent Pool (MPP) para comercializar novo antiviral contra influenza - Biolab &amp; Co\",\"isPartOf\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg\",\"datePublished\":\"2026-09-25T11:50:55+00:00\",\"dateModified\":\"2026-09-30T19:32:29+00:00\",\"description\":\"A Biolab & Co. foi selecionada pela Medicines Patent Pool (MPP) para oferecer ao mercado brasileiro o antiviral baloxavir marboxil, da Roche, nova tecnologia indicada para o tratamento da influenza.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#primaryimage\",\"url\":\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg\",\"contentUrl\":\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg\",\"width\":1600,\"height\":669},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biolabeco.com.br\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biolab &amp; Co. \u00e9 escolhida pelo Medicines Patent Pool (MPP) para comercializar novo antiviral contra influenza\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biolabeco.com.br\/#website\",\"url\":\"https:\/\/www.biolabeco.com.br\/\",\"name\":\"Biolab\",\"description\":\"Na Biolab &amp; Co, ci\u00eancia e cuidado caminham juntos. Saiba como promovemos sa\u00fade com responsabilidade socioambiental e tecnologia.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biolabeco.com.br\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biolab &amp; Co. is chosen by the Medicines Patent Pool (MPP) to market a new antiviral for influenza - Biolab &amp; Co.","description":"Biolab &amp; Co. was selected by the Medicines Patent Pool (MPP) to offer the Brazilian market the antiviral baloxavir marboxil, from Roche, a new technology indicated for the treatment of influenza.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biolabeco.com.br\/en\/press\/biolab-has-been-selected-by-the-medicines-patent-pool-mpp-to-commercialize-a-new-antiviral-for-influenza\/","og_locale":"en_US","og_type":"article","og_title":"Biolab &amp; Co. \u00e9 escolhida pelo Medicines Patent Pool (MPP) para comercializar novo antiviral contra influenza","og_description":"A Biolab & Co. foi selecionada pela Medicines Patent Pool (MPP) para oferecer ao mercado brasileiro o antiviral baloxavir marboxil, da Roche, nova tecnologia indicada para o tratamento da influenza.","og_url":"https:\/\/www.biolabeco.com.br\/en\/press\/biolab-has-been-selected-by-the-medicines-patent-pool-mpp-to-commercialize-a-new-antiviral-for-influenza\/","og_site_name":"Biolab &amp; Co","article_modified_time":"2026-09-30T19:32:29+00:00","og_image":[{"width":1600,"height":669,"url":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/","url":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/","name":"Biolab &amp; Co. is chosen by the Medicines Patent Pool (MPP) to market a new antiviral for influenza - Biolab &amp; Co.","isPartOf":{"@id":"https:\/\/www.biolabeco.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#primaryimage"},"image":{"@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg","datePublished":"2026-09-25T11:50:55+00:00","dateModified":"2026-09-30T19:32:29+00:00","description":"Biolab &amp; Co. was selected by the Medicines Patent Pool (MPP) to offer the Brazilian market the antiviral baloxavir marboxil, from Roche, a new technology indicated for the treatment of influenza.","breadcrumb":{"@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#primaryimage","url":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg","contentUrl":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg","width":1600,"height":669},{"@type":"BreadcrumbList","@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biolabeco.com.br\/"},{"@type":"ListItem","position":2,"name":"Biolab &amp; Co. \u00e9 escolhida pelo Medicines Patent Pool (MPP) para comercializar novo antiviral contra influenza"}]},{"@type":"WebSite","@id":"https:\/\/www.biolabeco.com.br\/#website","url":"https:\/\/www.biolabeco.com.br\/","name":"Biolab","description":"At Biolab &amp; Co, science and care go hand in hand. Find out how we promote health with social and environmental responsibility and technology.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biolabeco.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/imprensa\/18866"}],"collection":[{"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/imprensa"}],"about":[{"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/types\/imprensa"}],"version-history":[{"count":1,"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/imprensa\/18866\/revisions"}],"predecessor-version":[{"id":18867,"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/imprensa\/18866\/revisions\/18867"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/media\/18871"}],"wp:attachment":[{"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/media?parent=18866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/categories?post=18866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}